Acceleron Pharma Inc.

In milestone-heavy deal worth up to $3B total, the pharma makes a big commitment to late-stage candidate for retinal diseases

Approval marks the start of a new disease-modifying treatment paradigm for the rare disease and related indications

As the most advanced FSHD programs aim to reduce muscle cell death, the next wave is targeting the disease’s genetic cause

Plus: J&J’s Rybrevant raises the bar and updates from Harbinger, Gritstone, Merck, Immunovant, Evozyne, PTC  

Plus: BridgeBio gains on oral achondroplasia therapy data and updates from Esperion, Aclaris, Merck & Co., Voyager and more

Plus: Myers at the helm of Viridian, and updates from Novartis, 

Plus: Greene becomes chief investment officer at Hevolution, and updates from Aerami and Curate

Plus: New commercial head at Valneva, and updates from Aeglea and Viridian 

Plus: McKinsey vet Fleming joins Enavate and updates from Scholar Rock, Acelyrin and Anpac

Sotatercept meets primary and most secondary endpoints in Phase III pulmonary arterial hypertension study